Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Pulmonary arterial hypertension (PAH) is the second most common lung complication in antiphospholipid syndrome (APS) patients. However, the concurrent development of APS-related nonthrombotic PAH is rarely reported. Lack of awareness for group 1 PAH in APS patient may contribute to underdiagnosis of this condition. Herein, we reviewed the case of a 56-year-old female who was diagnosed with PAH related to APS that mimicked chronic thromboembolic pulmonary hypertension (CTEPH). It is crucial to be aware of the possibility of a group 1 PAH diagnosis, even though patients have already been diagnosed with CTEPH. Furthermore, a multidisciplinary approach and serial follow-up right heart catheterization with echocardiography are important to make a timely diagnosis and provide optimal treatment for APS-related PAH in patients with CTEPH-like clinical features.
Abstract
Pulmonary arterial hypertension (PAH) is the second most common lung complication in antiphospholipid syndrome (APS) patients. However, the concurrent development of APS-related nonthrombotic PAH is rarely reported. Lack of awareness for group 1 PAH in APS patient may contribute to underdiagnosis of this condition. Herein, we reviewed the case of a 56-year-old female who was diagnosed with PAH related to APS that mimicked chronic thromboembolic pulmonary hypertension (CTEPH). It is crucial to be aware of the possibility of a group 1 PAH diagnosis, even though patients have already been diagnosed with CTEPH. Furthermore, a multidisciplinary approach and serial follow-up right heart catheterization with echocardiography are important to make a timely diagnosis and provide optimal treatment for APS-related PAH in patients with CTEPH-like clinical features.
참고문헌 (9)
- Giannakopoulos B, "The pathogenesis of the antiphospholipid syndrome", N Engl J Med, 368(11), pp.1033~1044 (2013)
- Maioli G, "Lung disease in antiphospholipid syndrome", Semin Respir Crit Care Med, 40(2), pp.278~294 (2019)
- Miyakis S, "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS)", J Thromb Haemost, 4(2), pp.295~306 (2006)
- Hughson MD, "Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome", Hum Pathol, 26(7), pp.716~724 (1995)
- Lee JS, "Nonthrombotic proliferative vasculopathy associated with antiphospholipid antibodies : a case report and literature review", Mod Rheumatol, 29(2), pp.388~392 (2019)
- Cervera R, "Morbidity and mortality in the antiphospholipid syndrome during a 5-year period : a multicentre prospective study of 1000 patients", Ann Rheum Dis, 68(9), pp.1428~1432 (2009)
- Thenappan T, "Survival in pulmonary arterial hypertension : a reappraisal of the NIH risk stratification equation", Eur Respir J, 35(5), pp.1079~1087 (2010)
- 장영우, "A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort", Clinical Hypertension, 25(4), pp.39~44 (2019), 대한고혈압학회[DOI]
- Johnson SR, "Anticoagulation in pulmonary arterial hypertension : a qualitative systematic review", Eur Respir J, 28(5), pp.999~1004 (2006)